Triumvira Immunologics Announces Strategic Relationship for GMP Manufacturing with Centre for Commercialisation of Cancer Immunotherapy
Published: May 02, 2018
Established in 2016, the Centre for Commercialisation of Cancer Immunotherapy (C3i) is a Centre of Excellence for Commercialisation and Research from the Networks of Centres of Excellence. The mission is to accelerate access to innovative cancer immunotherapies for patients and offers an integrated structure for the development, translation and commercialization of groundbreaking therapies. C3i, which operates out of the Hôpital Maisonneuve- Rosemont in Montreal, Canada, combines four interacting units: GMP Manufacturing Unit for Regenerative Medicine and Cancer Immunotherapy; Biomarker-Diagnostic Unit; Clinical Research Unit; and Innovation and Commercialization Unit. For more information, visit: www.centrec3i.com
Affiliated to the Université de Montréal, Hôpital Maisonneuve-Rosemont (HMR) is part of CIUSSS-EMTL. The HMR has a major research center of close to sixty researchers. There are four distinct sectors at the national and international levels: immuno-oncology, vision health, nephrology and cell therapy. Each year, the HMR receives more than 4,000 students, future physicians, nurses and health care professionals. HMR’s cancer program supports one of the largest bone marrow transplantation unit in Canada and is recognized a Canadian leader in cell therapy.
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, with our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to firstname.lastname@example.org
Beth Kurth, + 1 617-374-8800, Ext. 106
CIUSSS de l'Est-de-l'Île-de-Montréal
Centre of Commercialisation of Cancer Immunotherapy (C3i)
Francois Bettez, B. Sc. M.Sc., 514-755-2516
Chief Executive Officer
Source: Triumvira Immunologics, Inc.